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rare diseases, consideration of alternative acceptance criteria for
public reimbursement /health service provision may be required.
PHP40
THE IMPACT ON DECISION-MAKING OF CHANGING COST-
EFFECTIVENESS OF HEALTH TECHNOLOGIES OVER TIME
Pang F1,Tolley K2
1Abbott Laboratories Ltd, Maidenhead, Berkshire, UK; 2MAPI VALUES,
Bollington, UK
OBJECTIVES: Estimation of cost-effectiveness of health tech-
nologies tends to focus on the time period at or around launch,
to fulﬁll the growing requirements of reimbursement or market
access agencies. This study reviews the factors which inﬂuence
cost-effectiveness over time and demonstrates the temporal
impact on cost-effectiveness using a number of case-studies. The
implications for decision making and market access are dis-
cussed. METHODS: A review of the factors that may inﬂuence
cost-effectiveness over time and methodological approaches used
to address these was conducted. Earlier analytical frameworks
of studies from the 1990s in the ﬁelds of motor airbags,
implantable cardiac deﬁbrillators, statins, renal dialysis and
hearing aids were revisited to re-estimate the cost-effectiveness.
For example, parameters of an economic evaluation conducted
in 1990 for erythropoetin were updated to 2004 values using a
recent systematic review of clinical evidence together with
revised unit costs and expert clinical opinion for resource utili-
sation. RESULTS: For the majority of case-studies examined,
there was a trend for the reduction in cost-effectiveness ratios
over time—e.g. for erythropoetin, the base-case cost per QALY
decreased ten-fold over a 14 year period (£216,906 to £21,547).
Signiﬁcant factors included unit costs, dosage, utility gains 
and revised discounted rates. CONCLUSIONS: The timing of
economic evaluation is critical in the estimation of cost-
effectiveness. Production of this evidence may often be the ﬁrst
time that the conceptual framework of economic analysis has
been applied to the technology, despite suggestions that eco-
nomic evaluation should be used iteratively throughout the
product life-cycle. This study has demonstrated that whilst 
there is a need for economic evaluation results to be timely to
aid decision-making (i.e. at or around launch), it is important
that the analysis is updated and reviewed periodically to assess
whether cost-effectiveness has changed sufﬁciently to justify
modifying the original decision.
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OBJECTIVES: To compare the quality of the health economic
material submitted to the Swedish Pharmaceutical Beneﬁts Board
and the Finnish Pharmaceuticals Pricing Board as part of 
the application for reimbursement for new pharmaceuticals.
METHODS: The health economic evaluations were reviewed in
each country against two checklists, marking each question
Yes/No/Not Applicable. The checklists used were: 1) the respec-
tive national Guidelines transformed into yes or no questions,
and 2) the QHES check list, a validated instrument, was also
used to provide a common comparator. The central estimate of
cost effectiveness was collected (cost per QALY) as well as
whether the application was accepted or rejected in each country.
RESULTS: The Swedish scores range from 0.24 to 0.87 and on
the QHES from 0.09 to 1, with a mean quality of 0.61 and 0.67
respectively. The Finnish scores range from 0.58 to 0.96 and on
the QHES from 0.28 to 0.84, with a mean quality of 0.76 and
0.62 respectively. The correlation between the respective national
guidelines and the QHES scores is modest (approx. 0.7 both in
Sweden and in Finland). This is mostly due to country speciﬁc
criteria. There was a low observed correlation between quality
score and acceptance in Sweden and also in Finland. Likewise,
the correlation between cost per QALY and decision to
accept/reject is low to medium. CONCLUSIONS: Health eco-
nomic material as part of applications to reimbursement agen-
cies varies widely in quality. There are differences even for the
same product in the two countries. Secondly, due to the relatively
small number of applications studied and the even fewer rejec-
tions, it is difﬁcult to draw ﬁrm conclusions regarding the value
the pricing authorities studied place on a QALY.
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OBJECTIVE: Medicare reform legislation requires the Medicare
Payment Advisory Commission (MedPAC) to conduct a study of
hospital pharmacy handling costs and to recommend whether
payment for handling costs of Part B speciﬁed outpatient drugs
should be made under the Medicare Hospital Outpatient
Prospective Payment System (OPPS). This study explores the
MedPAC approach to pharmacy departmental costs and poten-
tial reimbursement implications. METHODS: The MedPAC
rationale and recommendations were deconstructed, evaluated,
and compared to data about pharmacy operations obtained from
two studies. The ﬁrst study collected data from on-site observa-
tions of infusion therapy and related pharmacy activities in 24
hospital outpatient departments (HOPDs) located in 19 states.
A subsequent telephone survey gathered information about
stafﬁng and workﬂow from 30 other hospital pharmacy direc-
tors located in 16 states and the District of Columbia. RESULTS:
The MedPAC report places pharmacy costs into ﬁve categories;
concludes that hospitals can estimate these costs; and recom-
mends that hospitals develop and submit charges for a new set
of handling fee APCs. Findings from the comparative on-site
observations and telephone survey, however, reveal that signiﬁ-
cant portions of certain costs are not charged to the pharmacy.
For example, 69.1% of respondents had information systems
costs charged outside the department while 34.5% reported their
entire information systems costs charged elsewhere. Likewise,
73.3% of respondents reported reimbursement, chargemaster,
clerical and transport staff utilized by the pharmacy department
but not charged to the department. Such disparities in depart-
mental costing will signiﬁcantly hinder the uniform interpreta-
tion of costs assumed by MedPAC. CONCLUSIONS: Payment
methods in 2006 for handling costs of Part B separately paid
drugs will be derived in large part from the MedPAC recom-
mendations. If the payment methodology does not take existing
variations in recording pharmacy expense outside the depart-
ment, hospital providers may well be underpaid for handling
costs in 2006.
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